文献速递免疫规划传染病防控与疫情报告

BNT162b2疫苗两剂免疫后SARS-CoV-2刺突蛋白受体结合域总抗体与中和抗体的关联研究

Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine.
PubMed 文献 · Vaccine · 2021-07-24

本研究前瞻性纳入268名医护人员,在BNT162b2疫苗接种前、第1剂后20天及第2剂后30天检测抗SARS-CoV-2刺突蛋白受体结合域的总抗体(TAbs-RBD)和中和抗体(NAbs-RBD)。结果显示两剂后抗体水平显著升高,且TAbs-RBD与NAbs-RBD高度相关;高龄、吸烟和免疫抑制药物与第2剂后TAbs-RBD水平呈负相关。

要点

  • 第2剂BNT162b2疫苗后NAbs-RBD中位数百分比达95.31%,显著高于第1剂后的51.07%。
  • TAbs-RBD与NAbs-RBD在第1剂后(rho=0.861)和第2剂后(rho=0.989)均高度相关。
  • 高龄、吸烟和免疫抑制药物与第2剂后TAbs-RBD水平负相关,强调第2剂对老年人群的重要性。

核心结论

  • BNT162b2疫苗两剂后TAbs-RBD与NAbs-RBD显著相关,第2剂大幅提升中和抗体水平。
  • 高龄、吸烟和免疫抑制药物负向影响免疫后最终抗体水平,第2剂对老年人群尤为重要。

研究设计与样本

  • 前瞻性队列研究,纳入268名医护人员,在免疫前、第1剂后20天和第2剂后30天检测TAbs-RBD和NAbs-RBD。
  • 参与者平均年龄45.45岁(±11.93),范围24-70岁,女性211人(79.9%)。

主要发现

  • 第1剂后NAbs-RBD中位数(IQR)百分比为51.07%(31.60%),第2剂后为95.31%(3.70%),差异有统计学意义(P<0.001)。
  • 第1剂后20天,56/264(21.2%)参与者NAbs-RBD水平低,第2剂后1个月全部达到保护水平。
  • TAbs-RBD与NAbs-RBD相关性:第1剂后Spearman rho=0.861(P<0.001),第2剂后rho=0.989(P<0.001)。
  • 第2剂后TAbs-RBD与年龄(P<0.001)、吸烟(P=0.011)、免疫抑制药物(P<0.001)负相关,与BMI(P=0.004)和免疫后全身不良事件(P=0.001)正相关。

临床怎么用

  • 监测BNT162b2接种后抗体水平时可同时评估TAbs-RBD与NAbs-RBD,二者高度相关。
  • 对高龄、吸烟或使用免疫抑制药物者应重视完成第2剂接种以提升中和抗体水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA COVID-19 vaccine with epidemiological and clinical parameters are limited. METHODS: We prospectively measured the total (TAbs-RBD) and the neutralizing antibodies (NAbs-RBD) against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a cohort of 268 Healthcare workers before immunization, 20 days after the 1st dose and 30 days after the 2nd dose of the BNT162b2 vaccine. A statistical analysis for possible association of antibodies' levels with epidemiological and clinical parameters was performed. RESULTS: The mean age (±SD) of the participants was 45.45 years (±11.93) (range: 24-70 years) and 211 (79.9%) were females. Statistically significant differences were detected regarding both TAbs-RBD and NAbs-RBD between the first and second doses of the vaccine (P < 0.001). The median (IQR) percentage (%) of NAbs-RBD after the 1st dose was 51.07% (31.60%) and after the 2nd dose 95.31% (3.70%) (P < 0.001). The correlation between the TAbs-RBD and NAbs-RBD was after the 1st dose, Spearman's, rho: 0.861 (P < 0.001) and after the 2nd dose rho: 0.989 (P < 0.001). Twenty days after the 1st dose, 56/264 (21.2%) of the participants had low levels of NAbs-RBD, while one month after the 2nd dose all of them had protective levels of NAbs-RBD. After the 2nd vaccine dose, a statistically significant negative association of TAbs-RBD was detected for age (P < 0.001), smoking (P = 0.011), and immunosuppressive medications (P < 0.001), while a positive association was detected for BMI (P = 0.004) and systemic adverse events after immunization (P = 0.001). CONCLUSION: A significant correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Older age, smoking, and immunosuppressive medications negatively affected the final antibody level after SARS-CoV-2 immunization. Our findings emphasize the significance of the 2nd vaccine dose especially in the older age groups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Michos A, Tatsi EB, Filippatos F, et al. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine. Vaccine. 2021. PMID: 34400017. doi:10.1016/j.vaccine.2021.07.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。